← Back to patent-cliff list
Sodium Phosphate[32P]
Tier C — Watch / tradeSodium Phosphate[32P]
-
Originator
1996
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Not applicable
Indications (approved)：Essential thrombocythaemia, Polycythaemia vera
Regional status
US
-
EU
-
China
Approved
1996-01-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sodium Phosphate[32P]?
Approved indications include: Essential thrombocythaemia, Polycythaemia vera.
When does the Sodium Phosphate[32P] patent expire?
No public expiry year is available for Sodium Phosphate[32P] yet; this page updates once verified.
How do I get a quote for Sodium Phosphate[32P] intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04